Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study
British Journal of Clinical Pharmacology2018Vol. 84(8), pp. 1776–1788
Citations Over TimeTop 18% of 2018 papers
Elena Peeva, Martin R. Hodge, Elizabeth Kieras, Michael L. Vazquez, Kosalaram Goteti, Sanela Tarabar, Christine Alvey, Christopher Banfield
Abstract
These results support further evaluation of PF-04965842 for clinical use in patients with inflammatory diseases.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Safety and Tolerability of Gabapentin as Adjunctive Therapy in a Large, Multicenter Study(1999)81 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)